Following publication, the authors conducted additional experiments to determine the genetic background of PKR regulatory domain mutant mice used in this study \[[@pone.0205424.ref001]\], and in a related article demonstrated that some phenotypes were not replicated when using a different PKR mutant line on a different genetic background \[[@pone.0205424.ref002]\].

• The genetic background of the PKR regulatory domain mutant mice was not known to the authors at the time the in vivo experiments were conducted for the *PLOS ONE* article, and so was not reported \[[@pone.0205424.ref001]\]. Following the publication of this work, the authors conducted SNP genotyping analyses and determined that PKR regulatory domain mutant mice used in the experiments were on a 98.9% 129S1/SvImJ genetic background. Hence, for some of the experiments reported in the *PLOS ONE* article, the genetic background is different between mutant and control animals (Figures 1--5).

• Following publication of the *PLOS ONE* article \[[@pone.0205424.ref001]\], the authors repeated experiments *in vitro* using bone-marrow derived macrophages and in vivo in a mouse model of tuberculosis infection using a different PKR-deficient mouse line harboring a catalytic domain mutation \[[@pone.0205424.ref003]\] instead of a regulatory domain mutation \[[@pone.0205424.ref004]\]. In these follow-up experiments, both mutant and control animals were on a C57Bl/6J background. These experiments yielded different results than those reported in the *PLOS ONE* article: the authors did not observe a statistically significant difference in CFU in lung between WT and PKR-deficient mice in the mouse model of Mtb infection, as reported in detail in \[[@pone.0205424.ref002]\]. While these findings did not support the conclusions of the *PLOS ONE* article, they were not based on exact experimental replications, as noted in the following table.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                         *PLOS ONE* experiment                                                                                                                                                                 *EJI* experiment
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [Origin of PKR mutant lines]{.ul}                                                                                                                                                      Regulatory domain knockout as generated by Yang YL *et al*. *EMBO J*. *1995* \[[@pone.0205424.ref004]\]                                                                               Catalytic domain knockout as generated by Abraham N *et al*. *J*. *Biol Chem*. *1999* \[[@pone.0205424.ref003]\]

  [Genetic background]{.ul}                                                                                                                                                              Wild-type (WT) control: C57BL/6J\                                                                                                                                                     WT control: C57BL/6J\
                                                                                                                                                                                         Protein kinase R (PKR)--deficient: 98.9% 129S1/SvImJ                                                                                                                                  PKR-deficient: C57BL/6J

  [Infection protocol]{.ul}\                                                                                                                                                             Mtb (100--200 CFU) was administered for the aerosol infection on day 0. On day 1 a mean of 30 CFU were recovered from lungs of WT mice and 37 CFU from lungs of PKR-deficient mice.   Mtb (100--200 CFU) was administered for the aerosol infection on day 0. On day 1 a mean of 127 CFU were recovered from lungs of WT mice and 137 CFU from lungs of PKR-deficient mice.
  (The Glas-col Inhalation Exposure instrument was different in the two experiments as the two experiments were conducted in different BSL3 facilities.)                                                                                                                                                                                                                       

  [Th timing of outcome assessments]{.ul}\                                                                                                                                               Post-infection days 21, 70 and 168.\                                                                                                                                                  Post-infection days 14, 29, 57 and 120.\
  (Day 14--21 and day 57--168 can be defined as acute phase and chronic phase of infection respectively. Therefore, the stages assayed were same in *PLOS ONE* and *EJI* experiments).   \*The CFU burden in lungs of PKR-deficient mice was 4- to 10-fold lower than in WT mice in the chronic phase of infection.                                                            \*The CFU burden in lungs of PKR-deficient mice was not distinguishable from that of WT mice in the chronic phase of infection.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

• The differences between the *PLOS ONE* and *EJI* experiments are tabulated above. The macrophage experiments in *PLOS ONE* article \[[@pone.0205424.ref001]\] used WT mice on a C57BL/6J background and regulatory domain PKR KO mice on a 129S1/SvImJ background. The macrophage experiments in the *EJI* article \[[@pone.0205424.ref002]\] used WT mice on a C57BL/6J background and both regulatory domain and catalytic domain PKR KO mice, each on a C57BL/6J background, and observed that PKR sufficiency or deficiency did not impact macrophage activation. The *EJI* article also compared WT mice on a 129S1/SvImJ background and regulatory domain PKR KO mice on a 129S1/SvImJ background, similar to the mice used in \[[@pone.0205424.ref001]\], and observed that interferon-gamma alone caused macrophage activation to similar levels in both WT and mutant, suggesting that heightened macrophage activation could be a background effect. In the *EJI* article it was observed that there was no statistically significant difference in Mtb CFU burden between WT and catalytic domain PKR KO mice, both on the C57BL/6J background. The *EJI* study casts doubt on the candidacy of PKR as a target for HDT of TB.
